Table 3.
Characteristics of CMV reactivations on all patients treated with immunosuppressive therapy
| HC | HCS | RC | CP | P* | |
|---|---|---|---|---|---|
| Courses, no. (%) | 34 (34) | 25 (25) | 14 (14) | 26 (26) | |
| Courses in patients seropositive for CMV, no. (%) | 26 (76) | 18 (72) | 12 (86) | 19 (73) | NS |
| CMV reactivations in seropositive patients, no. (%) | 9 (35) | 2 (11) | 4 (33) | 4 (21) | NS |
| Peak CMV copies | |||||
| Median (range) | 1 400 (300-39 500) | 750 (650-850) | 762 (450-1 875) | 2 313 (1 200-268 000) | |
| Mean of log peak CMV copies (95% CI) | 3.3 (2.7-3.9) | 2.9 (2.1-3.6) | 2.9 (2.5-3.3) | 3.8 (2.0-5.6) | NS |
| D to peak CMV | |||||
| Median (range) | 54 (26-95) | 26 (24-27) | 23 (13-54) | 26 (21-34) | |
| Mean (95% CI) | 54 (37-72) | 26 (6-45) | 28 (0-58) | 27 (18-35) | .049 |
| Wk of positivity for CMV | |||||
| Median (range) | 5 (2-17) | 3 (2-4) | 4 (2-7) | 3 (2-5) | |
| Mean (95% CI) | 7 (3-12) | 3 (0-15) | 4 (0-7) | 3 (1-5) | NS |
HC indicates horse ATG/CsA; HCS, horse ATG/CsA/sirolimus; RC, rabbit ATG/CsA; CP, alemtuzumab; NS, not statistically significant.
*
P values are for the comparison among the 4 groups; P value is computed based on the ANOVA F test for the log-transformed peak CMV copies.